Is Jasper Therapeutics, Inc. (JSPR) a Buy, Sell, or Hold?
Jasper Therapeutics, Inc.
NASDAQ:JSPR
$0.7228 USD
$0.11 (18.9%)
- Volume
- 3.12M
- Average Volume
- 501.05K
- Market Capitalization
- $11.75M
- P/E Ratio
- -0.21
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $3.53
- Year Low
- $0.32
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.26
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jeetinder Singh Mahal |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | JSPR |
| CUSIP | 471871202 |
| CIK | 0001788028 |
| Web | https://jaspertx.com |
| Phone | 650 549 1400 |
| Currency | USD |
| Employees | 22 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.22 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.26 |
| Quick Ratio | 2.26 |
| Cash Ratio | 1.57 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -3.59 |
| Price / Cash Flow | -0.17 |
| Price / Book | 4.07 |
Price Target and Rating
| Average Stock Price Forecast | $3.00 |
| High Stock Price Forecast | $3.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -75.91% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.95 |
| Trailing P/E Ratio | -0.21 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-75.8M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -523.04% |
| Return on Assets | -263.09% |
Financials Score
| AltmanZ Score | -28.71 |
| Piotroski Score | 0.00 |
| Working Capital | 11.3M |
| Total Assets | 21.18M |
| Ebit | -55.73M |
| Market Cap | 9.88M |
| Total Liabilities | 17.78M |
Poll Results
About Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California. ...
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
2026-06-03 10:56:17
Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
2026-06-01 08:00:00
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value.
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 16:05:00
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.
Frequently Asked Questions
-
What is the current Jasper Therapeutics, Inc. (JSPR) stock price?
-
Jasper Therapeutics, Inc.(NASDAQ:JSPR) stock price is $0.7228 in the last trading session. During the trading session, JSPR stock reached the peak price of $3.53 while $0.315 was the lowest point it dropped to. The percentage change in JSPR stock occurred in the recent session was 18.9% while the dollar amount for the price change in JSPR stock was $0.11.
-
JSPR's industry and sector of operation?
-
The NASDAQ listed JSPR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of JSPR?
-
Luca Di Noto | Senior Vice President of Technical Operations
Thomas G. Wiggans | Executive Chairman
Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director
Herbert C. Cross | Chief Financial Officer & Corporate Secretary
Jeetinder Singh Mahal | President, COO, CEO & Director -
How many employees does JSPR have?
-
Number of JSPR employees currently stands at 22. JSPR operates from 2200 Bridge Pkwy, Redwood City, CA 94065, US.
-
Link for JSPR official website?
-
Official Website of JSPR is: https://jaspertx.com
-
How do I contact JSPR?
-
JSPR could be contacted at phone #650 549 1400 and can also be accessed through its website. JSPR operates from 2200 Bridge Pkwy, Redwood City, CA 94065, US.
-
How many shares of JSPR are traded daily?
-
The average number of JSPR shares traded daily for last 3 months was 501.05K.
-
What is the market cap of JSPR currently?
-
The market value of JSPR currently stands at $11.75M with its latest stock price at $0.7228